05:15 AM EDT, 08/27/2024 (MT Newswires) -- (Updates with the stock move in the headline and the second paragraph.)

Trinity Biotech ( TRIB ) said late Monday it received substantial additional orders for TrinScreen HIV and is increasing its 2024 sales revenue outlook for the product to $10 million from $8 million.

Shares of the company surged more than 75% in Tuesday's premarket activity.

Price: 3.59, Change: +1.54, Percent Change: +75.86